Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)
Phase 1 Study of Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: April Higbee, BSN
- Phone Number: 57456 816 861-4700
- Email: April.Higbee@va.gov
Study Locations
-
-
Missouri
-
Kansas City, Missouri, United States, 64128
- Recruiting
- Veteran's Administration Medical Center
-
Principal Investigator:
- Prateek Sharma, MD
-
Contact:
- Higbee, BSN
- Phone Number: 57456 816-861-4700
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Category 4-high-grade intraepithelial neoplasia
- Ages 18 or older
- signed Informed Consent Form
- signed Health Insurance Portability and Accountability Act (HIPAA) Authorization Form
Exclusion Criteria:
- Clinically relevant data suggesting an unknown disease and requiring further evaluation by the Primary Investigator.
- Patients with renal failure or organ transplants.
- Patients who have known allergic reactions to Proton Pump Inhibitors (PPI).
- Participation in another study that would interfere with study endpoints within 30 days prior to screening.
- Previous enrollment into the current study.
- Patient is the Investigator, his family member or employee at the investigational site.
- Patient known or suspected to be involved in alcohol or drug abuse.
- Known or suspected history of non-compliance with medications.
- Inability to follow the procedures of the study (e.g., due to language problems, psychological disorders)
- Patients receiving prohibited concomitant medications including PPIs, H2-blockers, sucralfate, misoprostol.
- Patients receiving prohibited concomitant medications including clopidogrel, ketoconazole, digoxin, diazepam, warfarin, phenytoin, emtricitabine/nelfinavir/tenofovir, atazanavir, citalopram, emtricitabine/rilpivirine/tenofovir, rilpivirine, nelfinavir, tricyclic antidepressants, baclofen, tacrolimus, cyclosporine, cilostazol, disulfiram, methotrexate, voriconazole.
- Pregnancy or intention to become pregnant during the course of study, breast feeding, or unwillingness to use a highly effective means of contraception (oral contraception or intrauterine device).
- Prescription Non-steroidal anti-inflammatory Drug (NSAID) or aspirin use: The patient must be able to stop these meds 1 week prior to screening and during treatment.
- History of upper gastrointestinal surgery, Zollinger-Ellison syndrome, esophageal stricture, peptic stricture, duodenal and ⁄ or gastric ulcer, esophageal motility disorders, Inflammatory Bowel Disease (IBD), AIDS, pancreatitis, malabsorption, severe cardiovascular or pulmonary disease, liver disease, active malignant disease, Scleroderma, diabetes mellitus, autonomic or peripheral neuropathy, myopathy, functional bowel disorder or any underlying disease or medication that might affect the lower esophageal sphincter pressure or increase the acid clearance time.
- Subject unable or unwilling to fully complete all stages of the study.
- Unable to sign informed consent or inability to give fully informed consent due to language problems, psychological disorder or mental deficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Secretrol
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse effect evaluation
Time Frame: 60 days
|
60 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- EP202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.